Moleculin Biotech Inc

NASDAQ:MBRXUnited States

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company has a pipeline of clinical programs for the treatment of tumors and viruses. It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).

Contact Information

Headquarters

5300 Memorial Dr Ste 950HOUSTON, TX, United States 77007-8274

Phone

713-300-5160

Fax

302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer

Walter Klemp

Chief Financial Officer, Executive Vice President

Jonathan Foster

Chief Scientific Officer

Donald Picker

Senior Chief Medical Officer

Paul Waymack

Independent Director

Michael Cannon